Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Jillian B. Thomsen net worth and biography

Jillian Thomsen Biography and Net Worth

CAO of Nektar Therapeutics

Jillian B. Thomsen was appointed Chief Accounting Officer in April 2008. She has over 20 years of financial reporting and accounting experience. In her current role, Ms. Thomsen oversees accounting, financial reporting, planning & analysis, Sarbanes-Oxley compliance, treasury, and tax functions at the company. Previously, she served as Vice President, Finance and Controller of Nektar.

Prior to joining Nektar in 2006, Ms. Thomsen was Deputy Controller of Calpine Corporation from September 2002 to February 2006. From December 1990 to May 2002, Ms. Thomsen performed various roles with Arthur Andersen starting as a staff accountant and concluding as a senior manager.

Ms. Thomsen holds a Masters of Accountancy degree from the University of Denver and a B.A. in Business Economics from Colorado College.

What is Jillian B. Thomsen's net worth?: The estimated net worth of Jillian B. Thomsen is at least $291,019.27 as of February 16th, 2023. Ms. Thomsen owns 313,497 shares of Nektar Therapeutics stock worth more than $291,019 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Thomsen may own. Learn More about Jillian B. Thomsen's net worth.
How do I contact Jillian B. Thomsen?: The corporate mailing address for Ms. Thomsen and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Jillian B. Thomsen's contact information.
Has Jillian B. Thomsen been buying or selling shares of Nektar Therapeutics?: Jillian B. Thomsen has not been actively trading shares of Nektar Therapeutics during the past quarter. Most recently, Jillian B. Thomsen sold 10,267 shares of the business's stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $3.00, for a transaction totalling $30,801.00. Following the completion of the sale, the chief financial officer now directly owns 313,497 shares of the company's stock, valued at $940,491. Learn More on Jillian B. Thomsen's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 272,472 shares worth more than $332,493.55. The most recent insider tranaction occured on December, 19th when insider Jonathan Zalevsky sold 51,115 shares worth more than $48,048.10. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 12/19/2024.

Jillian B. Thomsen Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/16/2023	Sell	10,267	$3.00	$30,801.00	313,497
11/16/2022	Sell	11,095	$3.57	$39,609.15	323,764
8/16/2022	Sell	2,006	$4.76	$9,548.56	334,859
5/16/2022	Sell	5,841	$3.95	$23,071.95	170,427
2/16/2022	Sell	2,363	$10.95	$25,874.85
8/16/2021	Sell	13,339	$13.83	$184,478.37
5/17/2021	Sell	13,391	$18.30	$245,055.30
1/28/2021	Sell	75,000	$18.62	$1,396,500.00
8/17/2020	Sell	1,367	$19.67	$26,888.89
2/18/2020	Sell	1,394	$22.35	$31,155.90
2/6/2020	Sell	37,500	$22.78	$854,250.00
11/18/2019	Sell	2,713	$17.97	$48,752.61
8/16/2019	Sell	1,809	$18.15	$32,833.35	92,668
5/16/2019	Sell	1,928	$31.37	$60,481.36
2/19/2019	Sell	1,808	$42.39	$76,641.12
2/4/2019	Sell	16,119	$42.16	$679,577.04
11/16/2018	Sell	4,016	$38.25	$153,612.00
5/16/2018	Sell	3,576	$83.39	$298,202.64
4/16/2018	Sell	13,881	$101.46	$1,408,366.26
2/16/2018	Sell	2,545	$82.94	$211,082.30
8/16/2017	Sell	2,648	$19.32	$51,159.36
3/20/2017	Sell	112,500	$19.69	$2,215,125.00
7/11/2016	Sell	100,000	$15.09	$1,509,000.00	106,809
5/17/2016	Sell	724	$13.58	$9,831.92	7,033
2/17/2016	Sell	716	$11.92	$8,534.72	5,158
2/10/2016	Sell	15,000	$11.49	$172,350.00	3,999
1/19/2016	Sell	15,000	$14.12	$211,800.00	3,999
12/3/2015	Sell	15,000	$15.87	$238,050.00	3,999
11/11/2015	Sell	15,000	$13.52	$202,800.00	3,499
10/6/2015	Sell	15,000	$10.99	$164,850.00	3,499
9/23/2015	Sell	10,000	$13.04	$130,400.00	3,499
12/22/2014	Sell	5,000	$15.56	$77,800.00

Jillian B. Thomsen Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $0.93

$0.90

$0.96

50 Day Range

MA: $1.19

$0.93

$1.45

2 Week Range

Now: $0.93

$0.46

$1.93

Volume

1,787,229 shs

Average Volume

1,795,548 shs

Market Capitalization

$171.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Most People Are Dead Wrong.

From Brownstone Research | Ad